New discovery could lead to vaccines for plague and bacterial pneumonias

Jan 25, 2011

There is an ongoing battle in the "war on terror" that remains mostly unseen to the public -- a race between scientists working to develop a vaccine to protect against plague and the terrorists who seek to use plague as a weapon.

"Governments remain concerned that bioweapons of aerosolized Yersinia pestis, the bacteria that causes plague, could kill thousands," said Stephen Smiley, a leading plague researcher and Trudeau Institute faculty member.

The anthrax scare that followed the terror attacks of September 11, 2001, made the threat of real and led to a surge in federal funding into research aimed at heading off such threats.

According to Dr. Smiley, there is no licensed plague vaccine in the United States. Together with postdoctoral associate Jr-Shiuan Lin, he is working to develop a vaccine that will protect members of the armed services and public from a "plague bomb."

Yersinia pestis is arguably the most deadly bacteria known to man. Plague infections of the lung, known as pneumonic plague, are extremely lethal. The bacteria, which grow both inside and outside the cells of the lung, usually lead to death within a week of infection.

Most of the plague vaccine candidates that have been studied aim to stimulate to produce plague-fighting . However, animal studies suggest that antibodies may not be enough to protect humans from pneumonic plague. The Smiley laboratory has shown that can also fight plague. The lab previously demonstrated that a single immunization with an stimulates the production of T cells that provide partial protection against pneumonic plague.

New data, reported in the current issue of The Journal of Immunology, show that a second immunization, or booster, improves the protection provided by T cells. "It is particularly exciting that the boost seems to improve protection by increasing a newly described type of T cell, which we call a Th1-17 cell," said Dr. Smiley. These cells have characteristics of both Th1 cells, which defend against intracellular bacteria, and Th17 cells, which specialize at killing extracellular threats.

This research is focused primarily on thwarting the use of plague as a bioweapon. However, small, natural outbreaks of plague continue to this day. A plague vaccine will protect against both naturally occurring outbreaks and those that have been manufactured.

Additionally, Dr. Smiley believes these Th1-17 cells may be important in fighting other kinds of pneumonia: "Bacterial pneumonia is one of the most common causes of death in hospitals and, like plague, many of these pneumonias are caused by bacteria that grow both inside and outside the cells of our bodies."

Explore further: Clipping proteins that package genes may limit abnormal cell growth in tumors

add to favorites email to friend print save as pdf

Related Stories

Plague researchers race to beat bioterrorists

Sep 20, 2010

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest ...

Mimic molecules to protect against plague

Jul 04, 2008

Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have ...

Man dies from plague in China, 11 others infected

Aug 02, 2009

(AP) -- Thousands of people have been placed under quarantine in a town in northwest China after a man died of pneumonic plague and 11 others were confirmed infected with the deadly lung infection, health authorities said.

Denver Zoo monkey dies of plague

May 22, 2007

A hooded capuchin monkey at the Denver Zoo has died of the plague, which officials suspect was transmitted by a squirrel.

The plague tracked in Denver

May 11, 2007

Denver officials warned people to stay away from squirrels as they monitored what could be an outbreak of the plague.

Lovastatin: a new weapon against plague?

Jun 04, 2010

An experimental study has revealed that lovastatin, a drug prescribed for the treatment of hypercholesterolemia, protects animals against the deadly effects of plague. This infectious disease is on the upsurge ...

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.